

From: SANTE DIRECTOR C
Sent: jeudi 24 juin 2021 08:44
To: [REDACTED]@euralia.eu'
Cc: SANTE DIRECTOR C
Subject: RE: About ExeVir | Request for a meeting

Dear [REDACTED],

I acknowledge receipt of your e-mail to Mr Ryan.
A reply is being prepared and will be sent to you shortly.

Kind regards,

[REDACTED]
On behalf of John F. Ryan



European Commission
Directorate-General for Health and Food Safety
Directorate C – Public health

HTC [REDACTED]
L-2920 Luxembourg
+352 [REDACTED]
[REDACTED]@ec.europa.eu

From: [REDACTED] <[REDACTED]@euralia.eu>
Date: 23 June 2021 at 11:24:21 CEST
To: "RYAN John-F (SANTE)" <[REDACTED]@ec.europa.eu>
Subject: About ExeVir | Request for a meeting

Dear M. Ryan,

I am contacting you on behalf of [ExeVir](#), in order to organize an exchange with the [REDACTED], [REDACTED]. (ExeVir is registered to the Transparency Register under number **180203343227-11**).

ExeVir is a clinical stage company harnessing its single domain antibody (VHH) technology platform to generate robust therapies providing broad protection against infectious diseases infections, including coronaviruses.

As a consequence, Exevir has followed with the greatest interest the adoption by the European Commission of the **EU Strategy on COVID 19 Therapeutics** in May 2021 – announcing among other the setting up of a therapeutics innovation booster with a view of authorising at least three new therapeutics by October. In this context, [REDACTED] already had the opportunity to present the company and its technology in the framework of a dedicated webinar that took place on 20 May 2021 and which was organised in a collaboration of the European Clusters Alliance, the European Commission, the Council of European BioRegions, and the European Cluster Collaboration Platform.

As a follow-up of this presentation [REDACTED] would very much appreciate having the opportunity to further exchange with in order to know more about the eligibility criteria of the therapeutics innovation booster and in the meantime to let you know more about ExeVir and all the potential of the technology under development in the framework of the fight against COVID 19 today – but also against infectious diseases tomorrow.

Given the tight timeframe on this dossier, he will make himself available at your earliest convenience in the coming days should you be interested in such an exchange.

I am at your disposal should you require any additional information.

Best regards,

[REDACTED] | [REDACTED]
[REDACTED] [@euralia.eu](mailto:[REDACTED]@euralia.eu)
Mob. +32 [REDACTED]

Rue Montoyer 25 | 1000 Bruxelles
Rue de l'Université 57 | 75007 Paris

